May 20, 2020 / 8:42 PM / 7 days ago

Gilead-Galapagos's drug meets main goals of ulcerative colitis study

May 20 (Reuters) - Gilead Sciences Inc and partner Galapagos NV said on Wednesday a higher dose of their experimental drug filgotinib showed greater effectiveness than placebo in a mid-stage study testing it in ulcerative colitis patients.

Filgotinib is being tested for inflammatory conditions including rheumatoid arthritis and Crohn's disease. (reut.rs/2Tmy9fO) (Reporting by Manojna Maddipatla in Bengaluru; Editing by Sriraj Kalluvila)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below